J&J Suspends Enrollment In Golimumab Trials Due To Distribution Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
Suspension is not expected to disrupt filing timeline for the rheumatoid arthritis drug, which is being developed with Schering-Plough.